Multicenter, Safety Follow-Up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta
E
Erik Imel, MD
Primary Investigator
Enrolling By Invitation
17 years or below
All
Phase
N/A
2 participants needed
1 Location
Brief description of study
To evaluate the safety of romosozumab in participants with osteogenesis imperfecta (OI) that have completed Study 20200105, regardless of whether they received investigational product (romosozumab) until the last protocol-specified dose or ended investigational product early
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Osteogenesis imperfecta
-
Age: 17 years or below
-
Gender: All
Completion of the Romosozumab arm in the 20200105 Amgen Pediatric OI Trial
Updated on
19 Mar 2026.
Study ID: ENDO-AMGEN-ROLLOVER
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
